不對(duì)稱(chēng)二甲基精氨酸(ADMA)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Asymmetrical Dimethylarginine (ADMA) ,etc. by FLIA (Flow Luminescence Immunoassay)
N,N-Dimethylarginine; NG,NG-Dimethylarginine dihydrochloride; Asymmetric Dimethylarginine
（注：?jiǎn)未位鞙y(cè)多因子不超過(guò)8個(gè)指標(biāo) ）
- 編號(hào)LMB301Ge
- 物種Pan-species (General，通用)相同的名稱(chēng)，不同的物種。
- 實(shí)驗(yàn)方法競(jìng)爭(zhēng)抑制
- 反應(yīng)時(shí)長(zhǎng)1.5h
- 檢測(cè)范圍0.98-1000ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.327 ng/mL.
- 樣本類(lèi)型serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格8指標(biāo)數(shù)7指標(biāo)數(shù)6指標(biāo)數(shù)5指標(biāo)數(shù)4指標(biāo)數(shù)3指標(biāo)數(shù)2指標(biāo)數(shù)1指標(biāo)數(shù)
- 價(jià)格¥ 3026¥ 3143¥ 3317¥ 3550¥ 3783¥ 4132¥ 4656¥ 5820 添加到價(jià)格計(jì)算器 計(jì)算器
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷(xiāo)商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)不對(duì)稱(chēng)二甲基精氨酸(ADMA)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的不對(duì)稱(chēng)二甲基精氨酸(ADMA)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 87-95 | 90 |
| EDTA plasma(n=5) | 79-102 | 82 |
| heparin plasma(n=5) | 83-92 | 87 |
| sodium citrate plasma(n=5) | 83-90 | 86 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的不對(duì)稱(chēng)二甲基精氨酸(ADMA)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中不對(duì)稱(chēng)二甲基精氨酸(ADMA)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 94-104% | 87-101% | 84-101% | 93-101% |
| EDTA plasma(n=5) | 82-90% | 95-102% | 93-101% | 79-103% |
| heparin plasma(n=5) | 81-90% | 81-98% | 89-102% | 78-93% |
| sodium citrate plasma(n=5) | 89-97% | 78-98% | 96-104% | 93-101% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品、樣本、磁珠、檢測(cè)溶液A）標(biāo)準(zhǔn)品或樣本50μL及磁珠10μL，加檢測(cè)溶液A50μL，
37°C酶標(biāo)板振蕩器孵育60分鐘；
3. 磁吸洗板3次；
4. 加檢測(cè)溶液B100μL，37°C振動(dòng)孵育30分鐘；
5. 磁吸洗板3次；
6. 加鞘液100μL，旋渦震蕩2分鐘后讀數(shù)。
實(shí)驗(yàn)原理
將不對(duì)稱(chēng)二甲基精氨酸(ADMA)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體包被于磁珠，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠、標(biāo)記VEGFA，標(biāo)記的不對(duì)稱(chēng)二甲基精氨酸(ADMA)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)和未標(biāo)記的不對(duì)稱(chēng)二甲基精氨酸(ADMA)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體競(jìng)爭(zhēng)結(jié)合，然后將未結(jié)合物洗凈后，加入PE標(biāo)記的親和素，再次徹底洗滌后即可上機(jī)讀數(shù)。MFI值和樣品中的不對(duì)稱(chēng)二甲基精氨酸(ADMA)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)呈負(fù)相關(guān)。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Pan-species (General，通用) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| CPB301Ge11 | 不對(duì)稱(chēng)二甲基精氨酸(ADMA)牛血清白蛋白偶聯(lián)物 | Immunogen; SDS-PAGE; WB. |
| CPB301Ge21 | 不對(duì)稱(chēng)二甲基精氨酸(ADMA)卵白蛋白偶聯(lián)物 | Immunogen; SDS-PAGE; WB. |
| PAB301Ge01 | 不對(duì)稱(chēng)二甲基精氨酸(ADMA)多克隆抗體 | ELISA, CLIA. / IHC-Fr, ICC, IP (predicted). |
| LAB301Ge71 | 不對(duì)稱(chēng)二甲基精氨酸(ADMA)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| CEB301Ge | 不對(duì)稱(chēng)二甲基精氨酸(ADMA)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMB301Ge | 不對(duì)稱(chēng)二甲基精氨酸(ADMA)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| KSB301Ge11 | 不對(duì)稱(chēng)二甲基精氨酸(ADMA)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| PLoS One. | Interactions among Vascular-Tone Modulators Contribute to High Altitude Pulmonary Edema and Augmented Vasoreactivity in Highlanders[PubMed: PMC3439466] |
| Cytokine | Effect of CCL5 on dimethylarginine dimethylaminohydrolase-1 production in vascular smooth muscle cells from spontaneously hypertensive rats.[Pubmed: 23834755] |
| Neurol Res. | Effect of 18β-glycyrrhetinic acid on cerebral vasospasm caused by asymmetric dimethylarginine after experimental subarachnoid hemorrhage in rats.[Pubmed:25475507] |
| Int J Clin Exp Med. | Correlation research on ADMA plasma levels and left ventricular function of peritoneal dialysis patients[Pubmed:25550968] |
| Clin Respir J | Asymmetric dimethylarginine contributes to airway nitric oxide deficiency in patients with COPD[PubMed: 26076870] |
| Cytokine | Dimethylarginine dimethylaminohydrolase-1 mediates inhibitory effect of interleukin-10 on angiotensin II-induced hypertensive effects in vascular smooth muscle cells of spontaneously hypertensive rats[PubMed: 26375520] |
| Neurological Research | Effect of 18β-glycyrrhetinic acid on cerebral vasospasm caused by asymmetric dimethylarginine after experimental subarachnoid hemorrhage in rats[PubMed: 25475507] |
| Scientific Reports | Dimethylarginine Dimethylaminohydrolase 2 (DDAH 2) Gene Polymorphism, Asymmetric Dimethylarginine (ADMA) Concentrations, and Risk of Coronary Artery Disease: A Case-Control Study[pubmed:27677852] |
| clinica chimica acta | Increased serum concentrations of asymmetric dimethylarginine (ADMA) in patients with early-onset coronary artery disease.[pubmed:27884754] |
| The?Journal?of?Physiology | Asymmetric?dimethylarginine?(ADMA)?elevation?and?arginase?up-regulation?contribute?toendothelial?dysfunction?related?to?insulin?resistance?in?rats?and morbidly obese humans.[pubmed:26840628] |
| Angiogenesis | Dimethylarginine dimethylaminohydrolase-1 (DDAH1) is frequently upregulated in prostate cancer, and its overexpression conveys tumor growth and angiogenesis by metabolizing asymmetric dimethylarginine (ADMA).[pubmed:29150732] |
| Scientific Reports | A Novel Role of Irbesartan in Gastroprotection against Indomethacin-Induced Gastric Injury in Rats: Targeting DDAH/ADMA and EGFR/ERK Signaling[Pubmed:29523851] |
| Mechanisms of?Ageing?and Development | Multivessel analysis of progressive vascular aging in the rat: Asynchronous vulnerability among vascular territories[Pubmed:29605639] |
| Nutrition, Metabolism and Cardiovascular Diseases | Arginine bioavailability and endothelin-1 system in the regulation of vascular function of umbilical vein endothelial cells from intrauterine growth restricted newborns[Doi: 10.1016/j.numecd.2018.09.002] |
| Biochemical?and?Biophysical?Research?Communications | Probucol improves erectile function via Activation of Nrf2 and coordinates the HO-1/DDAH/PPAR-γ/eNOS pathways in streptozotocin-induced diabetic rats[Pubmed: 30454888] |
| Brazilian?Journal?of?Pharmaceutical?Science | Demographic, clinical and lifestyle predictors for severity of erectile dysfunction and biomarkers level in Malaysian patients[] |
| ACS?Combinatorial?Science | Novel cellularly active inhibitor regresses DDAH1 induced prostate tumor growth by restraining tumor angiogenesis through targeting DDAH1/ADMA/NOS pathway[Pubmed: 30673277] |
| International Journal of the Cardiovascular Academy | Nebivolol prevents the increase of asymmetric dimethylarginine and oxidants in hyperhomocysteinemic rats[] |
| Oxid Med Cell Longev | The Role of Reactive Oxygen Species and Nitric Oxide in the Inhibition of Trichophyton rubrum Growth by HaCaT Cells[Pubmed: 32104540] |
| Molecular Medicine Reports | Blueberry anthocyanin?enriched extract ameliorates transverse aortic constriction?induced myocardial dysfunction via the DDAH1/ADMA/NO signaling pathway in?…[Pubmed: 31746378] |
| International Journal of Nephrology | Effect of a Supervised Peridialytic Exercise Program on Serum Asymmetric Dimethylarginine in Maintenance Hemodialysis Patients[Pubmed: 33163233] |
| Journal of Clinical Medicine | The Usefulness of Serum Biomarkers in the Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial[Pubmed: 32344735] |
| Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub | Levels of endothelial substances in patients with newly identified hypertension compared with healthy controls[33463628] |
| WIENER KLINISCHE WOCHENSCHRIFT | Non-functioning adrenal incidentalomas may increase toxic metabolites[34255169] |
| pharmaceuticals | Effect of a Low Dose of Carvedilol on Cyclophosphamide-Induced Urinary Toxicity in Rats—A Comparison with Mesna[34959638] |
| Int J Biochem Cell Biol | HIF-1α and Nrf2 regulates hypoxia induced overexpression of DDAH1 through promoter activation in prostate cancer[Pubmed:35644470] |